NasdaqCM:BLTEPharmaceuticals
A Look At Belite Bio (BLTE) Valuation As Tinlarebant NDA Submission Progresses
Belite Bio (BLTE) has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for tinlarebant, its oral therapy candidate for Stargardt disease type 1. This marks a key late stage regulatory step.
See our latest analysis for Belite Bio.
Despite the recent NDA progress and upcoming conference appearances, Belite Bio’s share price return over the past week and quarter has been slightly negative. Its 1 year total shareholder return is very large and its 3 year...